Aytu BioScience, Inc. Announces the Appointment of Gregory A. Gould as Permanent Chief Financial Officer
June 19, 2017 at 08:05 am EDT
Share
Aytu BioScience, Inc. announced the hiring of Gregory A. Gould as the company's full-time Chief Financial Officer, effective June 16, 2017 and following his tenure as Aytu's part-time CFO. Greg has worked with Aytu BioScience's management team since the company's inception in April 2015, and he has overseen all aspects of the company's finance functions inclusive of financial reporting, accounting, oversight of the company's financings, and various aspects of Aytu's corporate operations. Prior to joining Aytu BioScience on a full-time basis, he split his time between Aytu and Ampio Pharmaceuticals, Inc. from April 2015 until June 2017.
Aytu BioPharma, Inc. is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Companyâs Rx segment consists of prescription pharmaceutical products and the Consumer Health segment consists of various consumer healthcare products (the Consumer Health Portfolio). The Companyâs prescription products include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (ADHD); Karbinal ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions; and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Its Consumer Health Segment addresses a range of common conditions.
AYTU BIOPHARMA, INC. 
